Phapros Tbk PT Asset Resilience Ratio
Phapros Tbk PT asset resilience ratio. Phapros Tbk PT (PEHA) has an Asset Resilience Ratio of 5.12% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PEHA cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Phapros Tbk PT (2011–2025)
Asset resilience ratio of Phapros Tbk PT from 2011 to 2025. This chart shows how Phapros Tbk PT's Asset Resilience Ratio has changed over time. Read total liabilities of Phapros Tbk PT for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Phapros Tbk PT's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Phapros Tbk PT.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rp70.40 Billion | 5.08% |
| Short-term Investments | Rp620.61 Million | 0.04% |
| Total Liquid Assets | Rp71.02 Billion | 5.12% |
Asset Resilience Insights
- Limited Liquidity: Phapros Tbk PT maintains only 5.12% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Phapros Tbk PT Industry Peers by Asset Resilience Ratio
Compare Phapros Tbk PT's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Phapros Tbk PT Asset Resilience Ratio by Year (2011–2025)
Phapros Tbk PT asset resilience ratio by year from 2011 to 2025. The table below shows the annual Asset Resilience Ratio data for Phapros Tbk PT.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.08% | Rp70.40 Billion ≈ $4.13 Million |
Rp1.39 Trillion ≈ $81.28 Million |
+5.05pp |
| 2024-12-31 | 0.03% | Rp400.00 Million ≈ $23.44K |
Rp1.43 Trillion ≈ $83.79 Million |
-0.16pp |
| 2023-12-31 | 0.19% | Rp3.40 Billion ≈ $199.23K |
Rp1.77 Trillion ≈ $103.47 Million |
+4.47pp |
| 2022-12-31 | -4.28% | Rp-77.25 Billion ≈ $-4.53 Million |
Rp1.81 Trillion ≈ $105.84 Million |
-0.08pp |
| 2021-12-31 | -4.20% | Rp-77.15 Billion ≈ $-4.52 Million |
Rp1.84 Trillion ≈ $107.73 Million |
-2.84pp |
| 2020-12-31 | -1.36% | Rp-26.01 Billion ≈ $-1.52 Million |
Rp1.92 Trillion ≈ $112.27 Million |
-3.89pp |
| 2019-12-31 | 2.54% | Rp53.18 Billion ≈ $3.12 Million |
Rp2.10 Trillion ≈ $122.86 Million |
+2.64pp |
| 2018-12-31 | -0.11% | Rp-1.97 Billion ≈ $-115.14K |
Rp1.87 Trillion ≈ $109.50 Million |
-11.18pp |
| 2017-12-31 | 11.08% | Rp130.25 Billion ≈ $7.63 Million |
Rp1.18 Trillion ≈ $68.91 Million |
+11.66pp |
| 2013-12-31 | -0.59% | Rp-3.76 Billion ≈ $-220.58K |
Rp643.09 Billion ≈ $37.68 Million |
+0.07pp |
| 2012-12-31 | -0.66% | Rp-3.66 Billion ≈ $-214.69K |
Rp558.64 Billion ≈ $32.73 Million |
+0.19pp |
| 2011-12-31 | -0.84% | Rp-3.90 Billion ≈ $-228.29K |
Rp462.59 Billion ≈ $27.11 Million |
-- |
About Phapros Tbk PT
PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Generic Drugs Bearing (OCB); and Toll-in segments. It offers OTC drugs, including Antimo Anak, Antimo tablet, Livron B Plex, Becefort Sirop and tablet, Noza, Febrinex, Betafort suspensi, and Hemorogard. The company also provides … Read more